Business
UPDATE: ABVC BioPharma Announces 2024 Financial Results
Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available SILICON VALLEY, CA - April 16, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focuse...
About this update from Abvc Biopharma, Inc.
[{"type":"image","caption":"","headline":"ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States","size":{"original":{"width":140,"height":78,"url":"https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X_qKvHxujBtXyrHhszohog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7","width":140,"height":78}}},{"type":"text","content":"Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available","length":109,"tagName":"p"},{"type":"text","content":"SILICON VALLEY, CA - April 16, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leveraging its asset-light, partnership-driven model, today announced its financial results for the fiscal year ended December 31, 2024, marking a pivotal year of operational transformation and financial improvement.","length":455,"tagName":"p"},{"type":"text","content":"Revenue Growth of 234% Fueled by Global Licensing Milestones","length":60,"tagName":"p"},{"type":"text","content":"ABVC reported total revenues of $509,589 in 2024, representing a 234% increase compared to $152,430 in 2023. This significant growth was primarily driven by milestone payments collected from the Company's global licensing partners in CNS, oncology, and ophthalmology therapeutic areas.","length":289,"tagName":"p"},{"type":"text","content":"Importantly, ABVC remains eligible to receive up to an additional $18.3 million in milestone payments under existing licensing agreements, which, if received, will provide strong non-dilutive funding visibility to support future growth.","length":236,"tagName":"p"},{"type":"text","content":"Operating Expenses Reduced by 21% Reflecting Cost Discipline","length":60,"tagName":"p"},{"type":"text","content":"Total operating expenses were reduced to $5.21 million in 2024, down 21% from $6.62 million in 2023. The decline was primarily driven by:","length":137,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Selling, General and Administrative expenses red...